Novavax (NVAX) Competitors

Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Which has more volatility and risk, NVAX or MRNA?

Novavax has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.

Does the media favor NVAX or MRNA?

In the previous week, Novavax had 8 more articles in the media than Moderna. MarketBeat recorded 34 mentions for Novavax and 26 mentions for Moderna. Novavax's average media sentiment score of 0.69 beat Moderna's score of 0.17 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	10 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do insiders and institutionals have more ownership in NVAX or MRNA?

53.0% of Novavax shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Comparatively, 11.0% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is NVAX or MRNA more profitable?

Novavax has a net margin of 39.20% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	39.20%	-142.33%	28.65%
Moderna	-94.31%	-25.96%	-20.09%

Do analysts recommend NVAX or MRNA?

Novavax presently has a consensus price target of $15.86, suggesting a potential upside of 86.99%. Moderna has a consensus price target of $43.59, suggesting a potential upside of 69.87%. Given Novavax's stronger consensus rating and higher possible upside, equities analysts clearly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Which has better valuation & earnings, NVAX or MRNA?

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$682.16M	2.02	-$187.50M	$2.28	3.72
Moderna	$3.24B	3.09	-$3.56B	-$7.53	-3.41

Summary

Novavax beats Moderna on 11 of the 17 factors compared between the two stocks.